[PSS50] A Cost-Effectiveness Analysis of Secukinumab 300 Mg Vs Current Therapies for The Treatment of Moderate to Severe Plaque Psoriasis In Italy

[PSS50] A Cost-Effectiveness Analysis of Secukinumab 300 Mg Vs Current Therapies for The Treatment of Moderate to Severe Plaque Psoriasis In Italy

2015 Value in Health

D’Ausilio, A. | Aiello, A. | Daniel, F. | Graham, C. | Roccia, A. | Toumi, M. | Volume: 18, Issue: 7, Pages: A424,

Secukinumab (SEC300), an IL-17A antibody, was recently approved as highly effective therapy for moderate-to-severe plaque psoriasis (PSO). We examined the cost-effectiveness of SEC300 compared against other systemic biologic drugs: adalimumab (ADA), etanercept (ETA), infliximab (INF), ustekinumab (UST) 45 and 90 mg, and standard of care (SOC – cyclosporine and methotrexate) for plaque psoriasis, in the Italian National Health System (NHS) setting.

https://www.doi.org/10.1016/j.jval.2015.09.574